Lubripharm™ SSF
Our Sodium Stearyl Fumarate (SSF) excipients are backed by global regulatory audit approvals and designed to outperform traditional magnesium stearate. From consistent quality to patient-centric performance, we help manufacturers deliver safer, faster, and more effective medicines across dosage forms and therapeutic areas.
Lubripharm™ SSF
Certified, Patient-Focused, and Ready for Next-Gen Pharma
Sodium Stearyl Fumarate (SSF) excipients are engineered to meet the evolving needs of modern pharmaceutical manufacturing. With proven regulatory certifications, superior performance over traditional lubricants, and versatility across dosage forms and APIs, SSF helps manufacturers deliver high-quality, patient-friendly medicines with greater efficiency and reliability.
✅ Regulatory Confidence – Produced in certified facilities with global audit approvals [GMP/DMF/CEP/FCC]
✅ Superior to Magnesium Stearate – Offers improved wettability and lower hydrophobicity, minimizing hydrophobic film formation and supporting faster disintegration. Delivers better compactibility, lower ejection force, and reduced sensitivity to over-blending, making it well suited for unstable and sensitive APIs, while also maintaining lower moisture content
✅ Competition - Equivalent to leading industry solutions - controlled particle size, suitable specific surface area and moisture content
✅ Patient-Centric Formulations – Ideal for chewables, ODTs, sublingual, and swallow tablets with faster disintegration and better mouthfeel
✅ Designed for Continuous Manufacturing – Delivers reliable, consistent performance across extended production runs
✅ Therapeutic Application Versatility – Compatible with APIs for diabetes, cardiovascular, oncology, neurology, GLP-1, and other next-gen therapies
✅ Dosage Form Flexibility – Suitable for ODT, lozenges, hard capsules, softchew, sublingual, chewable, and immediate/modified release tablets
✅ Market-Ready Solutions – Flexible packaging options, closer-to-market support, and cost-effective performance
Example Therapeutic Areas Where SSF is Actively Used
Category |
Representative APIs / FDFs |
|
Antiretroviral / Antiviral |
Ritonavir, Nirmatrelvir, Dolutegravir, Lamivudine |
|
Antidiabetic |
Sitagliptin, Linagliptin, Saxagliptin, Alogliptin, Metformin, Gliptin combinations |
|
Antihypertensive / Cardiovascular |
Enalapril, Quinapril, Ramipril, Lisinopril, Perindopril, Felodipine, Doxazosin, Losartan, Telmisartan, Olmesartan, Candesartan, Azilsartan, Irbesartan |
|
Antidepressant |
Paroxetine |
|
Painkillers & Anticoagulants |
Tramadol, Clopidogrel, Gliptin derivatives in anticoagulant FDFs |
|
New & Targeted Therapies |
Finerenone |
Emerging API Compatibility with SSF
APIs Incompatible or Formulation-Sensitive with Magnesium Stearate
| API Name | Reason for Incompatibility or Sensitivity |
| Aspirin (acetylsalicylic acid) | Chemical interaction / accelerated degradation with MgSt in blends; aspirin is ester‑labile |
| Ibuprofen | Hydrophobic MgSt film reduces wettability → slower dissolution |
| Indomethacin | Hydrophobic barrier effects → reduced bioavailability risk if over‑lubricated |
| Ketoprofen | Dissolution interference from MgSt coating |
| Fenofibrate | Highly lipophilic API; MgSt hydrophobic film can slow wetting/dissolution |
| Ketorolac | Potential dissolution interference (hydrophobic barrier) |
| Diclofenac | Hydrophobic coating may delay dissolution |
| Amlodipine | Dissolution impact varies with salt/formulation; lubricant film risk |
| Felodipine | Hydrophobic layer can reduce release rate |
| Erythromycin | Hydrophobic interaction can delay dissolution; base is acid‑labile |
| Clarithromycin | Potential delay in dissolution (hydrophobic interaction) |
| Albuterol sulfate | Organic salt; MgSt can depress apparent solubility and wettability |
| Metoprolol tartrate / succinate | Organic salts; dissolution sensitivity to hydrophobic lubricants |
| Fosinopril sodium / Pravastatin sodium / Fluvoxamine maleate | Organic salt degradation or dissolution sensitivity dependent on pH & process |
| Moexipril | Acid–base sensitivity; ester hydrolysis risk |
| Promethazine HCl | Taste masking & organoleptic interference possible; lubricant level sensitive |
| Clopidogrel besylate / acetate | Dissolution variability; MgSt can reduce apparent solubility for ionized forms |
| Azathioprine | Sulfhydryl reactivity; excipient basicity can be problematic |
| Sulfasalazine | Moisture‑sensitive; lubricant film may delay wetting |
| Tramadol (esp. SR) | Release profile sensitive in sustained‑release systems |
| Glimepiride / Glipizide / Glibenclamide | Dissolution/tabletability can be lubricant‑level & mixing‑time sensitive |
| Cephalexin (β‑lactam) | Potential reactivity with metal ions; formulation‑dependent |
| Fosinopril sodium | Salt‑form degradation; pH‑dependent hydrolysis |
| Pravastatin sodium | Organic salt degradation under pH influence |
| Fluvoxamine maleate | Organic salt—dissolution/stability variability |
Download Our Resources
Related Applications
